Isolation and characterization of erlotinib-resistant human non-small cell lung cancer A549 cells

Ryujii Keda, Lee C. Vermeulen, Elim Lau, Zhisheng Jiang, Shannon M. Kavanaugh, Katsushi Yamada, Jill M. Kolesar

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is an effective therapy for non-small cell lung cancer (NSCLC). However, resistance to erlotinib reduces its efficacy. To investigate the basis of erlotinib resistance, we isolated erlotinib-resistant human NSCLC A549 cells, termed A549/ER cells. The A549/ER cells were found to be resistant to erlotinib, as well as paclitaxel and gemcitabine. We then performed a PCR array to investigate the resistance to erlotinib in A549/ER cells. EGFR expression in A549/ER cells was decreased compared to A549 cells. The expression of fibroblast growth factor 2 (FGF2) and p21 in A549/ER was increased when compared to A549 cells. Our results suggest that the down-regulation of EGFR and up-regulation of FGF2 is related to resistance to erlotinib in A549/ER cells.

Original languageEnglish
Pages (from-to)91-94
Number of pages4
JournalOncology Letters
Volume2
Issue number1
DOIs
StatePublished - Jan 2011

Keywords

  • Epidermal growth factor receptor
  • Erlotinib
  • Fibroblast growth factor 2
  • P21

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Isolation and characterization of erlotinib-resistant human non-small cell lung cancer A549 cells'. Together they form a unique fingerprint.

Cite this